Human papillomavirus type 16 E7-E6 fusion protein (or, for the natural splice isoform, HPV16 E6^E7 fusion protein) (HPV16 E7-E6 fusion protein, HPV16 E6^E7 (for the splice isoform))

Human papillomavirus type 16 E7-E6 fusion protein describes a chimeric molecule engineered by fusing two separate viral oncogenes, E6 and E7, from high-risk HPV16. Both E6 and E7 independently disrupt cell cycle regulation: E6 primarily degrades the tumor suppressor p53, while E7 inhibits the retinoblastoma protein (pRb)[2][3][5]. A naturally occurring splice variant, E6^E7, contains portions of both proteins and is implicated in maintaining oncogenic properties by stabilizing E6 and E7 and increasing cell proliferation[1]. Artificial fusion proteins (E6/E7 recombinant constructs) are used for research and vaccine development, able to elicit immune responses without toxic effects, and may aid the screening of anti-HPV agents[4]. Therapeutically, targeting E6/E7 interactions and their downstream pathways is central to HPV-related cancer interventions. Note: For clinical or structural annotation, clarify whether the context is the recombinant fusion protein, native HPV individual proteins, or the natural E6^E7 splice isoform. The canonical viral proteins are E6 and E7; "fusion protein" is artificial except in the case of the natural splice isoform E6^E7[1][4].

Other names

HPV16 E6^E7HPV16 E6/E7 fusion proteinHPV16 E6-E7 fusionHPV16 E6-E7 chimeric proteinE6-E7 recombinant protein

Inhibition of viral protein stability (HSP90 inhibition leads to decrease of E6, E7, and E6^E7 levels) Immune activation against E6/E7 antigens (vaccine-induced T cell responses)